Thomas E. Hughes, PhD
President, Chief Executive Officer
Dr. Tom Hughes has more than 30 years of industry experience in the development and commercialization of pharmaceutical products. Prior to joining Navitor, Dr. Hughes served as President and Chief Scientific Officer of Zafgen and previously led Zafgen as CEO from 2008 to 2017. During this time, Dr. Hughes established Zafgen as a leading biotechnology company working in the area of rare and prevalent metabolic disorders and led the company through its Initial Public Offering in 2014. Prior to Zafgen, Dr. Hughes held several positions at Novartis including Global Head of the Cardiovascular and Metabolic Diseases Therapeutic Area at the Novartis Institutes for BioMedical Research in Cambridge, MA. In these roles, he oversaw many drug discovery and development projects targeting major global aging-related health issues including obesity, diabetes, and heart disease. Dr. Hughes currently serves as a member of the Board of Directors of miRagen Therapeutics, Inc., and is a member of several scientific and strategic advisory boards, including Broadview Ventures, HotSpot Therapeutics, and FaunaBio.
Dr. Hughes holds a PhD in nutritional biochemistry from Tufts University, an MS in zoology from Virginia Polytechnic Institute & State University, and a BA in biology from Franklin and Marshall College.
James Randall “Randy” Owen, MD
Chief Medical Officer
James Randall “Randy” Owen has nearly 20 years of biopharma industry leadership experience in neuroscience drug development. Before joining Navitor, Dr. Owen served as Senior Vice President, Clinical Development and Chief Medical Officer at Acadia Pharmaceuticals Inc, where he led the development of pimavanserin, a 5HT2a inverse agonist, for the treatment of Parkinson’s disease psychosis as well as dementia-related psychosis, depression, and schizophrenias.
Prior to Acadia, he served as Vice President, U.S. Clinical Affairs at Lundbeck LLC, where he directed the evaluation of compounds across a range of neurological and psychiatric disorders, including pediatric epilepsies, stroke, Alzheimer’s disease, and neurogenic orthostatic hypotension.
Earlier in his career, he served in positions of increasing responsibility at Abbott (now Abbvie) and Merck, where he worked on an array of neuroscience compounds, including substance P antagonism and GABA subtype selective modulators. He also served as Group Director, Global Clinical Research at Bristol-Myers Squibb Company where he co-led the life-cycle management of aripiprazole during a period of product extensions in psychiatric indications in the United States and Europe.
Dr. Owen received his BA at Haverford College, his MD at East Tennessee State University, Quillen College of Medicine, and completed his psychiatric residency at Emory University.
Eddine Saiah, PhD
Chief Scientific Officer
Eddine Saiah has over 20 years of drug discovery, research, and development experience in biotechnology and pharmaceutical companies, and he has led the efforts in the advancement of more than ten new molecular entities into clinical development over his career. His expertise spans a broad range of drug targets for multiple diseases including diabetes, obesity, oncology, inflammation, cardiovascular, and pain. Before joining Navitor, he led the drug discovery and medicinal chemistry activities for several portfolio companies of Atlas Venture, including Raze Therapeutics and Quartet Medicine.
Previously, he served for a decade in senior R&D roles at Pfizer and Wyeth Research, which was acquired by Pfizer. Dr. Saiah was a Director of Medicinal Chemistry and Research Fellow at Pfizer, focused on R&D efforts in the inflammation, immunology, and rare disease research units. At Wyeth, he served in R&D roles of increasing responsibility and ultimately as the Head of Medicinal Chemistry for the Cambridge, MA site managing cardiovascular and metabolic disease programs as well as inflammation programs on a range of drug discovery targets including kinases, G protein-coupled receptors, proteases, nuclear hormone receptors, and protein-protein interactions.
Dr. Saiah was a postdoctoral research fellow at the Mayo Clinic’s Neuroscience Research Center. He received his PhD in chemistry from Pierre & Marie Curie University in Paris, France, and the Cancer Research Institute in Villejuif, France. Dr. Saiah is the co-author and co-inventor of more than 90 publications, scientific presentations, and patents.
Senior Vice President, Corporate Development
Rick Lundberg has nearly 30 years of strategic, operational, and commercial experience in the life sciences industry that ranges from de novo ventures to leading global biopharmaceutical companies. Mr. Lundberg is a member of the company’s founding team and has overall responsibility for corporate development, finance, and administration.
Prior to joining Navitor, Mr. Lundberg founded 7S BioVentures, which provided business development and corporate strategy advisory services to emerging life sciences companies. From 2006 to 2009, he was responsible for ex-U.S. commercial strategy and business development at Targanta Therapeutics. Previously, Mr. Lundberg led therapeutics business development initiatives and managed the genomics services business at Celera Genomics. He began his career at Biogen, where he served for nearly a decade in a broad range of business roles, including business development, program management, investor relations, sales, and marketing.
Mr. Lundberg holds a BA in Biochemical Sciences from Harvard University.